Oxurion Announces Two Presentations at The Macula Society 45th Annual Meeting
13 Juin 2022 - 07:00PM
Leuven, BELGIUM,
Boston, MA, US – JUNE
13,
2022 –
Oxurion NV (Euronext
Brussels: OXUR), a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, with clinical stage assets in vascular
retinal disorders, today announced that two presentations were
delivered at The Macula Society 45th Annual Meeting, June 8 -11,
2022 in Berlin, Germany.
The Macula Society presentations are available
under Conferences and Events within the Investors section of the
Company’s website.
TITLE: KALAHARI: Part A Results
of the Phase 2 Study of THR-149, a Plasma Kallikrein Inhibitor, in
Subjects with DME Responding Sub optimally to anti-VEGF
Treatment
PRESENTER: Shree K. Kurup, MD,
Dept. of Ophthalmology, University Hospitals, Cleveland, OH
SUMMARY:
- Multiple IVT
injections (up to 3) of THR-149 (0.01, 0.04, 0.13 mg) are safe and
well-tolerated
- In the high
dose group:
- A mean BCVA
gain of 6.1 letters was seen at Month 3, with gains observed up to
Month 6 as well as CST stabilization over the 6-month study period
compared to Baseline
- No need for
rescue treatment
- Post-hoc analysis, excluding 2
subjects with abnormalities on OCT, showed a mean gain in BCVA of
9.3 letters at Month 3, which was maintained up to Month 6
THR-149 is a potent plasma kallikrein inhibitor
being developed as a potential new standard of care for the up to
50% of diabetic macular edema (DME) patients showing suboptimal
response to anti-VEGF therapy. Oxurion is evaluating THR-149 for
the treatment of DME in Part B, the second part of its two-part
Phase 2 KALAHARI trial.
TITLE: THR-687, a Potent and
Highly Selective RGD Integrin Inhibitor in Development for the
Treatment of Diabetic Macular Edema
PRESENTER: Francesco Bandello,
Professor and Chairman of the Department of Ophthalmology,
VitaSalute, Milan, Italy
SUMMARY:
- Study
population was representative of treatment naïve DME patients based
on the CRC feedback on OCT at BL
- Mean BL BCVA
and CST values were aligned with naïve DME studies for other
compounds
- There was
insufficient evidence of efficacy on the key endpoints (BCVA and
CST)
- THR-687 is safe
and well tolerated
- No rescue
medication was administered to any of the subjects
- The ocular AEs
are consistent with the progressive nature of DME, no toxic drug
effects occurred
THR-687 is a highly selective pan-RGD integrin
antagonist that Oxurion had been developing as a first line therapy
for DME patients. Recently released data from Part A, the first
part of its two-part Phase 2 INTEGRAL trial showed THR-687 to be
safe and well tolerated with no serious adverse events and none of
the patients requiring rescue medication through Month 3, however,
there was insufficient evidence of efficacy on the key endpoints
(Best-Corrected Visual Acuity and Central Subfield Thickness). As a
result, Oxurion has decided not to advance THR-687 to Part B of the
INTEGRAL trial.
About
OxurionOxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, which are designed to improve and better
preserve vision in patients with retinal disorders including
diabetic macular edema (DME), the leading cause of vision loss in
working-age people, as well as other conditions. Oxurion intends to
play an important role in the treatment of retinal disorders,
including the successful development of THR-149, its novel
therapeutic for the treatment of DME. THR-149 is a potent plasma
kallikrein inhibitor being developed as a potential new standard of
care for the up to 50% of DME patients showing suboptimal response
to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium,
with corporate operations in Boston, MA. More information is
available at www.oxurion.com.
For more information, please
contact:
Oxurion NVTom GraneyChief Executive OfficerTel:
+32 16 75 13 10tom.graney@oxurion.com Michaël DillenChief
Business OfficerTel: +32 16 75 13 10michael.dillen@oxurion.com |
USConway Communications Beth
Kurth bkurth@conwaycommsir.com Westwicke, an ICR
CompanyChristopher BrinzeyTel: +1 617 835
9304chris.brinzey@westwicke.com |
- OXUR Macula Society Presentations 2022.0613
Oxurion NV (EU:OXUR)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Oxurion NV (EU:OXUR)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024